84 Original article

The antibacterial and antibiofilm activity of *Lactobacillus* acidophilus isolated from vagina against methicillin-resistant Staphylococcus aureus

Aleaa A. Jameel^a, Amenah R. Abdullah^a, Sahar I. Hussein^b

^aDepartment of Biology, College of Al-Rasheed, ^bDepartment of Biotechnology, College of Science, Baghdad University, Baghdad, Iraq

Correspondence to Aleaa A. Jameel, PhD, Department of Biology, Division Microbiology, College of Al-Rasheed, Baghdad, Iraq. Tel: +964 772 682 4660; e-mail: alyaa.abd@alrasheedcol.edu.iq

Received: 17 November 2021 Revised: 3 December 2021 Accepted: 4 December 2021 Published: 17 May 2022

Egyptian Pharmaceutical Journal 2022, 21:84–88

Background

Bacterial infections caused by the genus *Staphylococcus* represent a grave threat to both humans and animals, and they are a major concern to health authorities. Over the past few decades, methicillin-resistant *Staphylococcus aureus* (MRSA) has been recognized as the principal nosocomial pathogen worldwide.

Objective

To investigate the antibacterial and antibiofilm activity of *Lactobacillus acidophilus* against locally isolated MRSA at different concentrations.

Materials and methods

MRSA isolates were tested against some antibiotics for testing antibiotic sensitivity. The antibacterial activity of *L. acidophilus* based on the minimal inhibitory concentration (MIC) of *L. acidophilus* that inhibits the visible growth of MRSA isolates was assessed using the microdilution method. Estimation of MIC of *L. acidophilus* was done. Biofilm quantification assay was then used for the determination of the antibiofilm activity of *L. acidophilus*. The MIC concentration was assessed by a microtiter reader.

Results and conclusion

The antibacterial activity was tested by agar diffusion method and broth microdilution method. The microdilution method was used to determine the MIC of *L. acidophilus*, whereas the antibiofilm activity was determined by using 96-well polystyrene microtiter plates. The results revealed that *L. acidophilus* has antibacterial activity in a concentration-dependent manner. The average diameter zone of inhibition observed against MRSA isolates ranged from 11±0.5 to 18±0.5 mm Moreover, at subinhibitory concentration, this extract developed an isolate-specific antibiofilm effect and presented highly significant (*P*<0.05) variability in biofilm formation before and after addition of *L. acidophilus*. AA3 and AA12 isolates gave the lowest and highest antibiofilm activity, respectively. In conclusion, the supernatant of *L. acidophilus* is a promising alternative medication that can be used to treat the infection caused by MRSA.

Keywords:

antibacterial, antibiofilm formation, methicillin-resistant Staphylococcus aureus

Egypt Pharmaceut J 21:84–88 © 2022 Egyptian Pharmaceutical Journal 1687-4315

Introduction

The widespread therapeutic use of antimicrobials in humans and the administration of antimicrobials as growth promoters in food for animals have been associated with the development of resistant bacteria. Most antibiotics are administered to patients empirically before any diagnosis has been made based on results from cultures [1,2]. In one study, only 17% of methicillin-resistant Staphylococcus aureus (MRSA)-infected patients were initially given an effective antibiotic [3]. Such MRSA colonies may be present in an individual's global microbial population as part of the natural balance of his/her own microbial flora [4]. MRSA colonization generally precedes MRSA infection, and it plays a major role in the spread of this organism within human communities and health care facilities [5]. MRSA is a biofilmforming pathogen that adheres to numerous surfaces. In humans and animals, its main habitats are the nasal membranes and skin. Such colonies cause life-threatening infections such as pneumonia, sepsis, osteomyelitis, and endocarditis. Patients with MRSA colonization are often colonized for long periods of time. Approximately 50% of patients with MRSA infection are still colonized after 1 year [6].

Treatment with selected probiotic strains may be the ultimate answer to decolonization of MRSA because they do not increase the risk of multidrug resistance of

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

this pathogen [7]. The alarming increase in inappropriate antibiotic use along with bacterial resistance has led to renewed interest in ecological methods to prevent infections, which makes probiotics a very interesting field for further research. For example, a patient in Japan with a decubitus ulcer colonized by MRSA was successfully treated with a probiotic *Lactobacillus* preparation [8]. One nonantibiotic strategy to combat the bacterial infections involves the selection and promotion of endogenous bacterial flora to interfere with pathogenic bacterial adhesion [9]. Lactic acid bacteria (LAB) strains are potentially promising because they generate bactericidal bioactive peptides (bacteriocins) and enzymes that are able to control biofilm formation and the growth of the pathogens. Nisin is the best defined bacteriocin [10] produced by species Lactococcus that has been approved for use in food products [11]. Certain LAB strains have been reported to be highly antagonistic to biofilm-forming Staphylococcus aureus [12].

The genus Lactobacillus has a long history of safe use, especially in the dairy industry, and it plays a major role in the transformation of fermented milk and other food products. Over the past few decades, there has been increased impetus to introduce new Lactobacillus strains into foodstuffs with the goal of exerting a beneficial health effect when ingested by humans or animals [13]. Four types of LAB strains have been studied as competitive inhibitors of pathogenic organisms [11]. These strains are Lactobacillus casei 99p rhamnosus GG, L. casei shirota, Bifido bacterium breve yacult, and *Lactobacillus* acidophilus johnsonii [14]. Beneficial effects conferred by Lactobacilli, including inhibition of gram-negative and gram-positive pathogenic bacteria, were described by Charlier and colleagues, who reported that Lactococcus lactis had a specific antagonistic effect against S. aureus. Antimicrobial activity produced by LAB strains appears to be unrelated to the acidification of the medium. LAB strains were reported to exert a strong inhibitory effect on S. aureus growth in milk. Several suggestions have been proposed for inhibition of S. aureus by LAB. These include production of bacteriocins, hydrogen peroxide, and organic acids such as lactic and acetic acid [15].

Materials and methods

Microorganisms (isolation and identification)

L. acidophilus was obtained from the microbiology laboratory at the Department of Biotechnology, College of Science, University of Baghdad. This isolate was collected from vagina samples. Moreover, 15 MRSA isolates were obtained from the microbiology laboratory at Department of Biology, College of Science, University of Baghdad. These isolates were collected from different clinical infection site (nose, vagina, tongue, and wound pus). Identification was previously performed using 16SrRNA [16], whereas methicillin resistance was tested phenotypically via cefoxitin disk method [17] and molecularly via PCR technique [18].

Antibiotics sensitivity test

MRSA isolates were tested against the following antibiotics: oxacillin (5 μ g/disk), vancomycin (20 μ g/disk), imipenem (10 μ g/disk), gentamicin (10 μ g/disk), and erythromycin (15 μ g/disk).

Preparation of bacterial suspension

The inoculum was prepared as follows: a few colonies were picked from overnight bacterial cultures and were transferred into 5 ml of normal saline. Subsequently, it was adjusted to be balanced with a 0.5 McFarland tube to give 1.5×10^8 CFU/ml. Then, the bacteria were washed twice with phosphate buffer saline (PBS) after centrifugation for 20 min at 2000 rpm and resuspended in PBS again.

Antibacterial activity of Lactobacillus acidophilus

Agar diffusion method: the antibacterial activity of *L. acidophilus* was investigated by the agar well diffusion method as described by Al-Gbouri and Hamzah [17]. Five serial dilutions (80, 40, 20, 10, and 5 mg/ml) were achieved using PBS as a diluent. With the aid of a sterile cotton swab, the inoculum of bacteria (prepared as described previously) was uniformly spread on the surface of a Mueller-Hinton plate. Overall, 50 μ l of each dilution was added to each of the five wells (6 mm in diameter holes were cut in the agar). PBS alone was used as control. Finally, all plates were incubated anaerobically by using candle jar with presence of 5% of CO₂ overnight at 37°C. The resultant inhibition zones were measured in mm. Assays were carried out in triplicate.

Microdilution method: for determining the minimal inhibitory concentration (MIC) of *L. acidophilus* that inhibits the visible growth of MRSA isolates, the protocol mentioned by Andrews [18] was followed. The double serial dilutions of *L. acidophilus* were started from 0.087 to 80 mg/ml, which was prepared from a stock solution (100 mg/ml) using the Mueller-Hinton broth as a diluent. Further, an aliquot of 100 μ l of each dilution was distributed in microtiter plates. Control wells contained bacteria-free growth media

86 Egyptian Pharmaceutical Journal, Vol. 21 No. 1, January-March 2022

plus PBS. All wells were inoculated with $10 \,\mu$ l of a bacterial suspension ($1.5 \times 10^8 \,\text{CFU/ml}$). All trials were repeated in triplicate. Afterward, the microtiter plates were incubated aerobically for 24 h at 37°C.

Biofilm quantification assay: quantification of biofilm formation was assessed as described by Atshan et al. [19]. In brief, each isolate was propagated in tryptic soy broth containing 1% glucose at 37°C for 24h; thereafter. bacterial culture was adjusted to McFarland standard no. 0.5. A volume of 200 µl of an isolated culture was added to three wells of sterile 96-well polystyrene microplates. All plates were covered with their lids to avoid evaporation and incubated under aerobic conditions at 37°C for 24 h. Three wells filled with bacteria-free tryptic soy broth were considered as a negative control. After incubation, growth medium was carefully removed from the biofilm plate, gently washed thrice with distilled water, dried, and fixed at 60°C for 1h. Afterward, an aliquot of methanol (200 µl) was added to each well for 15 min at room temperature. Subsequently, the plates were washed thrice and covered with 0.1% crystal violet for 15 min at room temperature. Subsequently, plates were washed thrice with tap water and dried at 37°C for ~30 min. The adherent cells were resolubilized by the addition of 96% ethanol for 10 min. The absorbance of stained wells was determined at 630 nm with a microtiter reader (BioTek, USA).

Antibiofilm activity of *L. acidophilus* at MIC concentration: the same protocol was used for the biofilm formation assay that was previously mentioned. However, tryptic soy broth containing bacterial suspension (*L. acidophilus*) at MIC was added after biofilm formation. The microtiter plates

were incubated at 37°C for 24 h. After that, all wells were washed, stained, and read at 630 nm. Positive controls were performed as well by adding 200 μ l of *L. acidophilus*-free fresh bacterial suspension (compatible to 0.5 McFarland standard). The antibiofilm activity of samples was given as the percentage of inhibition and was expressed as follows:

%inhibition= $[OD_{630} \text{ of control (without bacterial suspension)}-(OD_{630} \text{ value in the presence of bacterial suspension)}/OD_{630} \text{ control}\times100]$ [20].

Statistical analysis

Data were presented as mean \pm SD. *t* test was employed for the evaluation of the efficacy of bacterial suspension (*L. acidophilus*). *P* value of less than 0.05 was considered significant.


Results and discussion

Regarding the susceptibility of bacteria to antibiotics, the results showed all tested isolates were resistant to all types of antibiotics (imipenem, erythromycin, oxacillin, gentamicin, and vancomycin), as shown in Fig. 1.

Determination of the effect of Lactobacillus acidophilus on methicillin-resistant Staphylococcus aureus

The results have shown that *L. acidophilus* has good antimicrobial efficacy against MRSA isolates in a concentration-dependent manner. The different concentrations of *L. acidophilus* showed inhibitory properties against all tested isolates. Relatively large zones of inhibition were seen: 18 ± 0.5 , 15 ± 0.5 , 13 ± 0.5 , and 11 ± 0.5 and 9 ± 0.5 mm at 80, 40, 20, 10, and 5 mg/ ml, respectively, as shown in Fig. 2. Antimicrobial activity of supernatant from *L*actobacillus *plantarum* (ADK2) isolate had a high inhibitory effect against *S*.






Antibiotic sensitivity of *Lactobacillus acidophilus* against some antibiotics (ERY, erythromycin; GEN, gentamicin; IM, imipenem; OXA, oxacillin; VA, vancomycin).

aureus and Pseudomonas aeruginosa with 34.18 and 38.43 mm, respectively [21]. The antimicrobial activity of purified biosurfactant of *L. plantarum* was examined against some microorganisms. The results showed that the biosurfactant had different antibacterial effect on the bacterial growth [22].

Estimation of minimal inhibitory concentration of Lactobacillus acidophilus

The antibacterial efficacy of the *L. acidophilus* calyces was evaluated using MIC assays. The results revealed that the MIC value was 8 mg/ml for all 15 MRSA isolates. The LAB strains were assayed for production

Figure 2



Inhibition zone of the *Lactobacillus acidophilus* isolated from vagina against methicillin-resistant *Staphylococcus aureus* at different concentration.

of antimicrobial substances such as bacteriocin, hydrogen peroxide, and organic acids using the agar well-diffusion technique described by Touré and colleagues.

Antibiofilm activity of Lactobacillus acidophilus

Biofilm production is considered as a marker of virulence. Numerous new approaches have been suggested for studying biofilm in terms of biofilm physiology and structure. In this study, the ability of biofilm-producing MRSA isolates was evaluated using presterilized 96-well polystyrene microtiter plates, which considered as a standard test for the detection of biofilm biomass [6,23,24]. Due to the crystal violet stained only the cells, not the slime materials and the cell, which is not in the biofilm structure is rinsed off by washing steps [23,24]. To estimate biofilm intensity, absorbance was determined at 630 nm by a microplate reader. Given that, absorbance values represented the intensity of the biofilm thickness that formed by the studied isolates on the surface of the microtiter well. The results of the current study summarized in Table 1 showed that all bacterial isolates were biofilm producer, but the biofilm intensity varies from one isolate to another. Approximately, 70% of isolates formed strong biofilm, whereas only 50% developed moderate biofilms according to OD630 limits (0.110-0.244 represented moderate biofilm. whereas OD630>0.244 represented the strong biofilm). To determine the effect of MIC of L. acidophilus on biofilm formation, 15 isolates were incubated with 10 mg/ml of the bacterial suspension; the results clarified that the MIC level was effective against all bacterial isolates. Yet, the effectiveness differs from one

Table 1 Biofilm formation by methicillin-resistant Staphylococcus aureus isolates before and after treatment with Lactobacillus acidophilus and percentage of inhibition

Isolates	Before treatment		After treatment		t test
	OD630±SD	Biofilm intensity	OD630±SD	Percentage of inhibition	
AA1	0.181	Moderate	0.159	10	7.72E-03
AA2	0.129	Moderate	0.101	22	2.57E-06
AA3	0.184	Moderate	0.161	9	6.62E-05
AA4	0.201	Moderate	0.104	45	2.21E-07
AA5	0.224	Moderate	0.103	51	1.11E-08
AA6	0.320	Strong	0.019	61	2.04E-10
AA7	0.380	Strong	0.099	70	8.65E-09
AA8	0.281	Strong	0.088	67	2.00E-09
AA9	0.291	Strong	0.082	69	2.71E-08
AA10	0.317	Strong	0.110	63	1.10E-09
AA11	0.453	Strong	0.241	44	6.62E-05
AA12	0.388	Strong	0.100	71	8.74E-10
AA13	0.221	Moderate	0.091	49	0.90E-08
AA14	0.118	Moderate	0.098	20	2.46E-05
AA15	0.281	Strong	0.079	67	2.51E-07

[Downloaded free from http://www.epj.eg.net on Tuesday, June 28, 2022, IP: 185.112.232.89]

88 Egyptian Pharmaceutical Journal, Vol. 21 No. 1, January-March 2022

isolate to another and presented highly significant (P < 0.05) variability in biofilm formation either with or without the addition of L. acidophilus. The lowest antibiofilm activity was exhibited in AA3 isolate with 9% inhibition, whereas the AA12 gave the strongest antibiofilm activity. The percentage of inhibition was 71%. These results indicated that the L. acidophilus at MIC level inhibits the biofilm formation of MRSA isolates. Antibiofilm activity of the L. plantarum cellfree supernatants (CFS) showed good stability in the presence of different chemicals including EDTA, SDS, and tween 80. High stability of the CFS in the presence of the mentioned chemicals indicates its stable antibiofilm potential to be used as biopreservatives and pharmaceutical compounds. Antibiofilm potential of L. plantarum CFS was completely inhibited by proteinase K. This finding has been reported previously for bacteriocins produced by L. plantarum, indicating the role of bacteriocins in biofilm inhibition of the CFS from L. plantarum spp. [25,26]. In addition, antibiofilm activity of the CFS was not strongly affected by the lipase, which shows the antibiofilm activity is not dependent on the lipid compounds of the CFS.

Conclusion

The supernatant of *L. acidophilus* is a promising alternative medication that can be used to treat the infection caused by MRSA.

Financial support and sponsorship Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Anderson MEC, Lefebvere SL, Weese SJ. Evaluation of prevalence and factors for methicillin-resistant *Staphylococcus aureus* colonization in veterinary personnel attending an international equine veterinary conference. Vet Microbiol 2008; 129:410–417.
- 2 Roghmann MC, McGrail L. Novel ways of preventing antibiotic-resistant infections: What might the future hold?. Am J Infect Control 2006; 34:469–475.
- 3 Crum NF, Lee RU, Thornton SA, Wollace MR, Barrozo C, Keefer-Norris A, et al. Fifteen-years study of the changing epidemiology of methicillinresistant Staphylococcus aureus. Am J Med 2006; 19: 943–995.
- 4 Alvarez-Olmoz M, Oberherman RA. Probiotic agents and infections diseases: modern perspective on a traditional therapy. Clin Infect Dis 2001; 32:1567–1876.
- 5 Bradley SF. Eradication or decolonization of methicillin-resistant Staphylococcus aureus carriage: what are we doing and why are we doing it?. Clin Infect Dis 2007; 44:186–189.

- 6 Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin RH, et al. Randomized controlled trial of chlorhexidine gluconate for washing intranasal mupirocin and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant *Staphylococcus aureus* colonization. Clin Infect Dis 2007; 44:178–185.
- 7 Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends Biotechnol 2003; 21:217–223.
- 8 Huttunen E, Noro K, Yang Z. Purification and identification of antimicrobial substances produced by two *Lactobacillus casei* strains. Int Dairy J 1995; 5:503–513.
- 9 Millette M, Le Tien C, Smoragiewicz W, Lacroix M. Inhibition of *Staphylococcus aureus* on beef by nisin-containing modified alginate films and beads. Food Control 2007; 18:878–884.
- 10 Ammor S, Tauveron G, Dufour E, Chevallier I. Antibacterial activity of lactic acid bacteria against spoilage and pathogenic bacteria isolated from the same meat small-scale facility. 1. Screening and characterization of the antibacterial compounds. Food Control 2006a; 17:454–461.
- 11 Maragkoudakis PA, Zoumpopoulou G, Miaris GH, Kalantzopoulos G, Pot B, Tsakalidou E. Probiotic potential of *Lactobacillus* strains isolated from dairy products. Int Dairy J 2006; 16:189–199.
- 12 Nomoto K. Prevention of infection by probiotics. J Biosci Bioeng 2005; 100:583–592.
- 13 Charlier C, Even S, Gautier M, Le Loir Y. Acidification is not involved in the early inhibition of *Staphylococcus aureus* growth by *Lactococcus lactis* in milk. Int Dairy J 2008; 18:197–203.
- 14 Martineau F, Picard FJ, Roy PH, Ouellette M, Bergeron MG. Speciesspecific and ubiquitous-DNA-based assays for rapid identification of *Staphylococcus aureus*. J Clin Microbiol 1998; 36:618–623.
- 15 Jaddoa NT, Al-Mathkhury HJ. Biofilm shows independency form hemolysin genes arsenal in methicillin-resistant *Staphylococcus aureus*. Iraqi J Sci 2018; 59(4C):2184–2194.
- 16 Delvechio VG, Petroziello JM, Gress MJ, McCleskey FK, Melcher GP, Crouch HK, Lupski JR. Molecular genotyping of methicillin-resistant Staphylococcus aureus via fluorophore-enhanced repetitive-sequence PCR. J Clin Microbiol 1995:33:2141–2144.
- 17 AL-Gbouri NM, Hamzah AM. Evaluation of *Phyllanthus emblica* extract as antibacterial and antibiofilm against biofilm formation. Iraqi J Agri Sci 2018; 49:142–151.
- 18 Andrews JM. Determination of minimum inhibitory concentration. J Antimicrob Chemother 2001; 48(Suppl.S1):5–16.
- 19 Atshan SS, Nor Shamsudin M, Sekawi Z, Lung LT, Hamat RA, Karunanidhi A, et al. Prevalence of adhesin and regulation of biofilm-related genes in different clones of *Staphylococcus aureus*. J Biomed Biotechnol 2012; 6:1–10.
- 20 Wang Q, Sun FJ, Liu Y, Xiong LR, Xie LL, Xia PY. Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBCpositive and-negative clinical isolates of *Staphylococcus epidermidis*. Antimicrob Agents Chemother 2010; 54:2707–2711.
- 21 Jameel AA, Haider NH. Determination of the optimum conditions for biosurfactant production by local isolate of *Lactobacillus plantarum* and evaluate its antimicrobial activity. Iraqi J Agr Sci 2021; 52:170– 188.
- 22 Jameel AA, Haider NH. Study the antimicrobial and antiadhesive activity of purified biosurfactant produced from *Lactobacillus plantarum* against pathogenic bacteria. Iraqi J Agr Sci 2021; 52:1194–1206.
- 23 Touré R, Kheadr E, Lacroix C, Moroni O, Fliss I. Production of antibacterial substances by bifidobacterial isolates from infant stool active against Listeria monocytogenes. J Appl Microbiol 2003; 95:1058–1069.
- 24 Gad GFM, EI-Feky MA, EI-Rehewy MS, Hassan MA, Abolella H, Abd El-Baky RM. Detection of i c a A, *icaD* genes, and biofilm production by *Staphylococcus aureus* and *Staphylococcus epidermidis* isolated from urinary tract catheterized patients. J Infect Dev Ctries 2009; 3:342–351.
- 25 Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, Ruzicka F. Quantification of biofilm in microtiter plates: an overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 2007; 115:891–899.
- 26 Olaleye Tolulope M. Cytotoxicity and antibacterial activity of methanolic extract of Hibiscus sabdariffa. J Med Plants Res 2007; 1:009–013.